Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)

NCT06241573 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06241573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06241573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lunsayil LTE: An Extension Trial Assessing Long-term Spesolimab Treatment in Patients With Hidradenitis Suppurativa (HS)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2/3
Overall status
Terminated
Start date
May 8, 2024
Completion date
April 11, 2025
Enrollment
39 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)